Spire Wealth Management’s Royalty Pharma RPRX Stock Holding History

Spire Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,195	Closed	-$37.2K	–	2528
2025 Q1	$37.2K	Sell	1,195 -954	-44%	-$30.2K	﹤0.01%	1392
2024 Q4	$54.8K	Buy	2,149 +1,699	+378%	+$45.1K	﹤0.01%	1248
2024 Q3	$12.7K	Hold	450	–	–	﹤0.01%	1574
2024 Q2	$11.9K	Hold	450	–	–	﹤0.01%	1597
2024 Q1	$13.7K	Hold	450	–	–	﹤0.01%	1621
2023 Q4	$13.1K	Hold	450	–	–	﹤0.01%	1671
2023 Q3	$12.2K	Hold	450	–	–	﹤0.01%	1666
2023 Q2	$13.8K	Hold	450	–	–	﹤0.01%	1717
2023 Q1	$16.2K	Hold	450	–	–	﹤0.01%	1692
2022 Q4	$18K	Hold	450	–	–	﹤0.01%	1411
2022 Q3	$18K	Buy	+450	New	+$19.2K	﹤0.01%	1375

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Spire Wealth Management's RPRX Position: Q2 2025 in Review

Spire Wealth Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 1,195 shares — an estimated $37.2K sold.

Spire Wealth Management first reported a position in RPRX in Q3 2022 and held it in 11 quarters. The position peaked at $54.8K in Q4 2024. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

Spire Wealth Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
Spire Wealth Management sold 1,195 Royalty Pharma shares in Q2 2025, an estimated $37.2K.
Spire Wealth Management first reported a position in Royalty Pharma in Q3 2022 and held it in 11 quarters.
Spire Wealth Management's Royalty Pharma position peaked at $54.8K in Q4 2024.
454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Spire Wealth Management's 13F filing for Q2 2025, filed 4 Aug 2025.